Clinical Trial Detail

NCT ID NCT02251548
Title A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute, Pharmacyclics
Indications

chronic lymphocytic leukemia

pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma

postgerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma

Therapies

Cyclophosphamide + Fludarabine + Ibrutinib + Rituximab

Age Groups: adult

No variant requirements are available.